Family from Mumbai, India to the INR in 2015 & May 2017
Family from Mumbai, India on their second visit to the INR, in May 2017. First visit and treatment at the INR was in November 2015, four years after her stroke. The family discusses her neurological improvement after her first treatment at the INR. Her neurological improvement increased month after month and now has been sustained for 1 1/2 years and counting.
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2018 INR PLLC, all rights reserved.
Patient traveled from Colorado to the INR in Boca Raton, Florida, in April 2017.
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2017 INR PLLC, all rights reserved.
Sustained neurological improvement 2 1/2 years after stroke. Treatment at the Institute of Neurological Recovery in Boca Raton, Florida, in April, 2017.
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2018 INR PLLC, all rights reserved.
Patient is from Papua New Guinea, where he has been living for more than 17 years. Improvements noted in chronic central post-stroke pain, motor function and balance documented within minutes of treatment, 18 months after stroke. Treatment at the Institute of Neurological Recovery in Boca Raton, Florida on April 13, 2017.
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2018 INR PLLC, all rights reserved.
“Perispinal Etanercept for Traumatic Brain Injury” is Chapter 7 of the medical textbook New Therapeutics for Traumatic Brain Injury. See the abstract and links below:
“Abstract
Brain dysfunction after traumatic brain injury (TBI) may involve a persistent neuroinflammatory response that can last for years following acute brain insult. This neuroinflammatory response may include microglial activation and persistence of excess levels of tumor necrosis factor (TNF) in the brain, resulting in perturbation of brain function. TNF, in addition to its role as the master regulator of the inflammatory response, is a key regulator of synaptic function in the brain. Experimental data suggest that etanercept, a selective TNF inhibitor, may ameliorate microglial activation; modulate the adverse synaptic effects of excess TNF; and favorably intervene in basic science models of TBI, stroke, subarachnoid hemorrhage, and Alzheimer’s disease. Perispinal administration is a therapeutic method designed to use the cerebrospinal venous system to enhance selective delivery of etanercept across the blood–cerebrospinal fluid barrier. Increasing clinical data suggests that perispinal etanercept (PSE) has therapeutic utility for treatment of selected brain disorders associated with elevated TNF, including chronic neurological dysfunction following stroke and various forms of brain injury. PSE is an emerging treatment modality for TBI.”
- Edward Tobinick, Rodriguez-Romanacce H, Kinssies R, Kim N. PSE FOR TRAUMATIC BRAIN INJURY. Chapter 7 In: Heidenreich KA, editor. New Therapeutics for Traumatic Brain Injury. Cambridge, Mass.: Academic Press; 2017. p. 109-29. LINK. (first published October 2016).